The therapeutic efficacy of herpes simplex virus thymidine kinase / ganciclovir ( HSV -tk / GCV ) system in many types of tumors is unsatisfactory due to the insufficient spread of gene transfer and insufficient cell killing. In the current study, we investigated whether adenovirally delivered monocyte chemoattractant protein ( MCP ) -1 potentiates the antitumor effects of the HSV -tk / GCV system in hepatocellular carcinoma ( HCC ) cells. Subcutaneous tumor foci of the human HCC cell line, HuH7, established in athymic mice were directly transduced with a recombinant adenovirus ( rAd ) harboring an HSV -tk gene driven by a human -fetoprotein promoter, followed by GCV administration. Subsequently, another rAd expressing MCP -1 under the universal CAG promoter was injected. The growth of tumors was markedly suppressed by codelivering HSV -tk and MCP -1 genes compared to that by either HSVtk / GCV or MCP -1 delivery. In the tumor tissues, monocyte / macrophage infiltration was detected immunohistochemically. The antitumor effects of the rAd expressing MCP -1 were markedly reduced by the administration of carrageenan, a compound known to inactivate macrophage. These results indicate that adenovirally delivered MCP -1 enhanced the antitumor effects of the HSV -tk / GCV system synergistically by recruitment / activation of macrophages in tumor tissues, suggesting an effective immunotherapy for HCC and other lineages of tumors when used adjuvantly with a suicide gene. Cancer Gene Therapy ( 2001 ) 8, 695 -704 
H epatocellular carcinoma (HCC ) is one of the most common malignancies with a poor prognosis throughout the world population because it frequently recurs shortly after surgical or nonsurgical treatments, including transcatheter arterial chemoembolization, percutaneous ethanol injection therapy, and chemotherapy. 1 -4 This is because tumor cells can survive even after combined treatments and progress to locally recurrent and distant metastatic lesions. To overcome these clinical problems, newly established treatments, such as gene therapy, can be combined with the conventional treatments to completely kill the tumor.
Gene therapy strategies for cancer are divided into three major categories: enzyme /prodrug systems such as suicide gene therapy, 5 -7 immune gene therapy, 8, 9 and tumorsuppressor gene replacement therapy. 10 -12 Tumor celltargeted gene therapy with a suicide gene under the transcriptional control of a tumor-specific promoter, such as the herpes simplex virus thymidine kinase (HSV-tk ) gene driven by a HCC -specific -fetoprotein ( AFP ) promoter, has been reported to have limited effects on some experimental models. 5 -7 This is due to incomplete gene transfer and cell killing, even when a highly tumoricidal suicide gene is delivered with a highly transducible recombinant adenovirus (rAd ) vector. 13 The suicide gene HSV-tk exhibits tumor cell killing activity in the presence of prodrug ganciclovir (GCV ) ( herpes simplex virus thymidine kinase /ganciclovir, HSVtk /GCV, system ) 14 not only in the infected cells, but also in neighboring uninfected cells via bystander effect 15 in vitro and in vivo. The bystander killing of neighboring uninfected tumor cells is thought to be not only due to the efflux of toxic phosphorylated GCV metabolites from HSV-tk -expressing cells to uninfected tumor cells through gap junctions, 16 but also due to the immune -mediated antitumor effects via macrophages, T lymphocytes, or natural killer (NK ) cells involving HSV-tk -expressing tumor cells. 17, 18 If so, the enhancement of host immune responses by a cytokine gene combined with the HSV-tk /GCV system may exert synergistic effects. Although several types of immunotherapy using cytokines have been used to enhance the bystander effect of HSV-tk xenogeneic cells, 17, 19, 20 satisfactory results have not yet been obtained for many types of tumors, including HCC.
Monocyte chemoattractant protein (MCP) -1 is a chemokine 21 that regulates the recruitment and activation of monocytes / macrophages to inflammatory sites and tumor tissues. Activation includes lysosomal enzyme release and tumoricidal activity in both mice and humans. 22 Because MCP -1 has been shown to regulate the chemotaxis and tumoricidal effects of blood monocytes, it may be an important mediator of tumor regression. Previous studies indicated that the transfectant -derived MCP -1 could recruit monocytes to tumor tissues and eventually cause tumor regression. 23 -25 However, transiently expressed MCP -1 could not achieve the antitumor effects in glioma cells. 26, 27 Some tumors express MCP -1 endogenously, 28, 29 and recently it was suggested that endogenous expression of MCP -1 in breast cancer cells leads to angiogenesis and tumor progression. 30 In the current study, we investigated whether adenovirally delivered MCP -1 potentiates the antitumor effects of the HSV-tk /GCV system in HCC cells in vivo. The results indicated that adenovirally delivered MCP -1 enhanced the antitumor effects of the HSV-tk /GCV system by the recruitment / activation of monocytes /macrophages in tumor tissues, suggesting an effective immunotherapy for HCC and other lineages of tumors when used adjuvantly with a suicide gene.
MATERIALS AND METHODS

Recombinant adenovirus
Recombinant replication -defective adenovirus vector AxCAMCP -1 (Fig 1A ) harboring the human MCP -1 gene 21 driven by the CAG promoter 31 was prepared, purified, and titrated according to the protocols supplied by the manufacturer (Takara, Tokyo, Japan ). Briefly, the MCP -1 gene fragment was excised by ClaI restriction enzyme from the pBluescript MCP -1 containing the HpaI-EcoRV fragment covering the MCP -1 gene. The resultant fragment was inserted into the ClaI site of the pAxCAwt cosmid ( Takara ) containing nearly full length of adenovirus type 5 genome lacking E1 and E3 regions to generate pAxCAMCP-1. Eventually, the rAd AxCAMCP-1 was generated by transfecting 293 cells with pAx-CAMCP-1 and EcoT22I digested adenovirus 5 -dIX DNA -terminal protein complex. 32 The rAds AxA2ANZ, 33 AxA2ANCre, 33 and AxA2ATK 34 ( Fig 1B ) that express lacZ, Cre recombinase, and HSV-tk, 35 respectively, under the control of (AB ) 2 S 6 AFP promoter were prepared. The rAd AxCANZ is identical to AxCAMCP -1 except that the MCP-1 gene was replaced by the lacZ gene, 31 generously gifted by Dr. Izumu Saito. These rAds were propagated in 293 cells as previously described. 33 Virus stocks were prepared using the standard protocol. 36 The titer of rAd was determined by the 50% tissue culture infectious dose ( TCID ) method. 37 
Cell line and cell culture
The human AFP -producing HCC cell line HuH7 38 was used in the present in vitro and in vivo experiments. Cells were cultured in Dulbecco's modified Eagle medium ( DMEM ) ( Gibco, Long Island, NY ) supplemented with 10% heatinactivated fetal bovine serum (Gibco).
Enzyme -linked immunosorbent assay ( ELISA ) for MCP -1
In a 12 -well tissue culture plate, aliquots of 8Â10 4 HuH7 cells were seeded in 1.5 mL of culture medium. Twentyfour hours later, the rAd AxCAMCP-1 was infected at various multiplicities of infection (MOIs ) (MOI= 1, 10, and 50 ). For control purposes, rAd AxCANZ was infected at an MOI of 50. Every 24 hours, the medium was collected from the wells and replaced with the same volume of fresh medium. From duplicated plates, cells were harvested and the collected viable cells per well were counted. The concentration of MCP-1 in the collected medium for each well was determined by ELISA as described previously. 39 Each well of a 96 -well microtiter plate (Nalgene, Rochester, NY ) was coated with 0.05 M carbonate buffer (pH 9.6) containing monoclonal antihuman MCP -1 antibodies ( ME61; 1 g/ mL ) overnight at 48C. After washing with phosphate -buffered saline ( PBS ) containing 0.05% polyoxyethylene (20 ) sorbitan monolaurate (Wako, Osaka, Japan ), the plates were blocked with PBS containing 1% bovine serum albumin for 1 hour at 378C and washed. Subsequently, diluted conditioned media or solution containing varying concentrations of the recombinant MCP -1 was added to the duplicate wells and incubated for 2 hours at 378C. Following incubation, the plates were washed and incubated first with rabbit anti -MCP-1 antibodies ( 1 g/mL ), followed by alkaline phosphatase -conjugated goat antirabbit antibodies (1 / 12,000; Tago, Burlingame, CA ) ( both for 2 hours at 378C and washed as above ). Aliquots of 1 mg /mL pnitrophenylphosphate ( Sigma, St. Louis, MO ) in 1 M diethanolamine (Sigma) ( pH 9.8 ) supplemented with 0.5 mM MgCl 2 were added as substrate and incubated for 40 minutes at room temperature. After reaction was stopped by the addition of 1 M NaOH, the optical density at 405 nm ( OD 405 ) was assessed using an ELISA plate reader ( MTP -120; Corona Electric, Ibaraki, Japan ). The total amount of MCP-1 produced per well per day ( ng /well / day ) was derived from the MCP -1 concentration (ng /mL ) multiplied by the volume of the medium collected ( mL / well /day ).
Myeloperoxidase ( MPO ) assay
Thioglycolate -elicited peritoneal macrophages were collected as described previously. 40 Briefly, 6 -week -old male BALB / cA Jcl mice (CLEA Japan, Tokyo, Japan ) received an intraperitoneal injection of 2 mL of 3% fluid thioglycollate medium (Wako). Four days later, the mice were sacrificed under anesthesia with diethylether ( Wako ), followed by peritoneal lavage with 10 mL cold PBS. Ninety percent of the collected peritoneal cells expressed both Mac -1 (CD11b ) and I-A d MHC class II when stained with phycoerythrin -conjugated anti -Mac -1 antibody (M1 /7; Pharmingen, San Diego, CA ) and fluorescein isothiocyanate -conjugated I -A d MHC class II (AMS -32.1; Pharmingen ) and quantitated by flow cytometric analysis on an EPICS 1 Elite (Coulter, Hialeah, FL ). Because MCP -1 elicits the MPO release from macrophages, the biological activity of MCP-1 produced by HuH7 cells that were infected with the rAds carrying MCP-1 gene was quantitated as follows. 41 An aliquot of 10 6 collected peritoneal macrophages that had been preincubated with cytochalasin B (5 g /mL ) ( Sigma ) for 15 minutes at 378C was incubated for 45 minutes at 378C in 200 L conditioned medium of HuH7 cells (2.5Â10 4 /mL ) that had been infected with rAds, AxCAMCP -1, or AxCANZ ( MOI = 50, 10, and 2 ) 2 days before the initiation of culture. Thereafter, 100 L of supernatants was harvested and incubated for 10 minutes at room temperature with 100 L of 0.1 M citrate /phosphate buffer (pH 5.0 ) containing 0.001% hydrogen peroxide ( Sigma ) and 0.01 M o -phenylendiamine-dihydrochloride (Wako ), a chromogenic substrate of MPO. The enzymatic reaction was stopped by the addition of 50 L of 2 M H 2 SO 4 and optical density at 492 nm (OD 492 ) was assessed using an ELISA plate reader (MTP-120; Corona Electric ). The relative activity of MPO ( %) in the supernatant was calculated from the following formula: [ 100Â( experimental OD 492 À spontaneous OD 492 ) /(maximal OD 492 À spontaneous OD 492 ) ]. Maximal MPO activity was determined by the lysis of macrophages by detergent ( 1% Triton X -100; Sigma). Spontaneous MPO release from macrophages incubated in culture media was quantified. Spontaneous OD 492 was less than 25% of maximal OD 492 in all assays.
Cytotoxicity assay ( 51 Cr release assay )
Cytolytic activities of macrophages were assessed by a chromium release assay, as previously described. 42 Briefly, 1Â10
6 HuH7 cells were incubated with 0.3 mCi Na 2 51 CrO 4 ( NEN Life Science Products, Boston, MA ) at 378C for 1 hour. After cells were washed, they were used as target cells. Balb /c mouse peritoneal macrophages were obtained as described in the MPO assay procedures, and incubated with 2 U /mL of IFN -( Pharmingen ) for 4 hours and with 100 ng /mL of LPS, Escherichia coli O55:B5 (List Biological Laboratories, Campbell, CA ) for 1 hour, and used as the effector cells. An aliquot of 5Â10 3 target cells was seeded in a well of 96 -well plates with the same number of 5Â10 3 apoptotic or viable HuH7 cells. For the preparation of apoptosis cells, HuH7 cells were treated with mitomycin C ( Sigma ) or HSV-tk / GCV system. HuH7 cells were prepared by 1 hour incubation with 0.1 mg / mL of mitomycin C at 378C. To induce apoptosis by HSV-tk /GCV system, HuH7 cells were infected with rAd carrying HSV-tk at an MOI of 30 followed by 50 g /mL of GCV treatment for 3 days. Cells were harvested and dead cells were determined by trypan blue dye exclusion test. The effector cells were added at varying effector / target ( E /T ) ratios in a final volume of 200 L and incubated for 18 hours at 378C and then 51 Cr release was determined. Percent specific cytotoxicity was calculated according to the following equation: [ 100Â(experimental release À spontaneous release )/( maximal release À spontapontaneous release )]. Spontaneous release was determined in wells with the target cells alone, and maximal release was achieved in wells with the target cells lysed in 1% Triton X.
ELISA for tumor necrosis factor -( TNF -)
TNF -concentrations in culture media obtained from the experiment in cytotoxicity assay were determined with AN'ALYZA mouse TNF -immunoassay (Genzyme THECHNE, Minneapolis, MN ) in accordance with the manufacturer's protocol.
Flow cytometric analysis
To detect apoptosis of HuH7 cells infected with rAdharboring HSV-tk gene, the cells were seeded on a culture dish and infected with the rAd at an MOI of 30. Twenty -four hours later, the supernatant was substituted with fresh culture medium supplemented with 50 g /mL of GCV. Three days later, cells were collected, washed twice with PBS, and stained with propidium iodide (PI ) (Trevigen, Gaithersburg, MD ). Stained cells were quantitated by flow cytometric analysis on an EPICS 1 Elite.
Animal experiments
Six -week -old male athymic mice (BALB /cA Jcl -nu; CLEA Japan ) were subcutaneously injected with 1Â10 7
HuH7 cells on day 0. On days 3 and 4, 2Â10 7 TCID 50 ( 100 L ) of rAd AxA2ATK, AxA2ANZ, AxA2ANCre, or PBS was injected into the tumor foci. Subsequently, 70 mg /kg of GCV ( Tanabe Pharmaceutical Drug, Tokyo, Japan ) was administered into the peritoneal cavity for five consecutive days ( day 5 -9 ). On day 7, 3Â10 7 TCID 50 (100 L ) of rAd AxCAMCP -1, AxCANZ, or PBS was injected into the subcutaneous tumors. In an experimental group, 1 mL of 2 mg /mL carrageenan (Sigma), a compound known to inactivate macrophage in vivo, 43 was administered into the peritoneal cavity of the mice on days 3, 4, 5, 6, 7, 14, 21, and 28. Tumor sizes were measured every 3 days and the volumes were calculated using the following equation: [ (the longest diameter )Â( the shortest diameter ) 2 SAKAI, KANEKO, NAKAMOTO, ET AL: IMMUNE-GENE THERAPY WITH MCP -1 AND SUICIDE GENE zinc -buffered formalin, embedded in paraffin, sectioned ( 2 m ), and stained with hematoxylin and eosin. Animal experiments were conducted according to the institutional guideline.
Immunohistochemical analysis
Tumor tissues were embedded in OCT compound (Sakura Finetek, Torrance, CA ) and snap -frozen in liquid nitrogen. Cryostat sections of frozen tissues were fixed in cold acetone for 10 minutes, followed by three rinses in PBS. To avoid nonspecific staining, avidin and biotin of tissues were blocked using a blocking kit (Vector Laboratories, Burlingame, CA ). After the blocking reaction, slides were incubated with biotin -conjugated anti -Mac -1 ( CD11b ) antibody (1:100 ) (M1 /7; Pharmingen ) for 30 minutes at room temperature. Biotin -conjugated rat IgG 2b , k, was used as the negative control. The reaction was visualized using Vectastain ABC Standard Kit ( Vector Laboratories ), followed by counterstaining with hematoxylin. Serial sections were fixed in 10% zinc -buffered formalin and stained with hematoxylin and eosin.
Statistical analysis
Results are expressed as means ± SE. Differences between groups were analyzed for statistical significance using the Mann -Whitney U test.
RESULTS
Production of MCP -1 in HuH7 cells by rAd AxCAMCP -1 infection
To evaluate the rate and duration of MCP-1 production in HuH7 cells infected with rAd containing an MCP -1 gene, AxCAMCP -1, the amounts of MCP -1 produced every 24 hours were monitored by ELISA (Fig 2 ) . MCP -1 was produced in a significant amount within 24 hours when infected at MOIs of 50 and 10, and reached a peak level on day 3 and remained at the levels for five subsequent days. The level of MCP -1 production rapidly decreased between days 5 and 7 followed by a gradual decrease after day 7. At an MOI of 1, MCP-1 production was low, but detectable, and MCP -1 was detected even 15 days after infection at all MOIs studied. In contrast, MCP-1 was not detected in cells infected with the control rAd, AxCANZ. In addition, at all MOIs, the numbers of viable cells continued to increase and reached a plateau 11 days after infection. These results indicated that amounts of MCP -1 produced by the infection of the rAd AxCAMCP -1 at MOIs of 50 and 10 were extremely high during the initial 5 days and lasted for more than 15 days in vitro. Moreover, even at an MOI of 1, the infected HuH7 cells produced MCP -1, suggesting high levels of MCP -1 expression at MOIs of greater than 1 and long -lasting expression in vitro.
Biological activity of MCP -1 in HuH7 cells produced by rAd AxCAMCP -1 infection
The biological activity of MCP -1 secreted from HuH7 cells infected with the rAd AxCAMCP -1 was determined using an MPO assay, in which MPO released from mouse peritoneal macrophages in response to MCP-1 concentration was assessed (Fig 3A ) . As expected, MOI-dependent activity of MPO was detected when macrophages were incubated with the conditioned medium of HuH7 cells infected with the rAd at MOIs of 10 and 50, but not at an MOI of 2, which was consistent with the amounts of secreted MCP-1 quantitated by ELISA ( Figs 2 and 3B ). The activity was undetectable when infected with the rAds without a MCP-1 gene, such as AxCANZ. The results show that MCP-1 produced and secreted from HuH7 cells is biologically functional with respect to the ability to activate macrophages derived from the mice that were syngeneic to those used in the following animal experiments.
TNF -production and tumoricidal activity of macrophages exposed to apoptotic HuH7 cells
We next examined whether HuH7 apoptosis might affect tumoricidal activity of neighboring mouse macrophages using cytotoxicity assay and ELISA for TNF -. In cytotoxicity assay, macrophages were coincubated with either apoptotic HuH7 cells, which were induced by mitomycin C treatment or HSV-tk /GCV, or viable HuH7 cells (Fig 4A ) . Percent viability of HSV-tk / GCV -treated HuH7 cells was 15%. At an E /T ratio of 10, 51 Cr release from labeled target cells coincubated with apoptotic HuH7 was comparable with that coincubated with viable HuH7 cells. However, at an E /T ratio of 100, 51 Cr release was relatively high when coincubated with apoptotic HuH7 cells, although it was not significant (Fig 4A ) . TNF -is known as a tumoricidal cytokine, 44 and is released from macrophages when activated. We assessed whether macrophages produce TNF -when they were exposed to apoptotic tumor cells ( Fig 4B ) . At an E / T ratio of 10, TNF -production was not increased in coincubation with apoptotic HuH7 cells induced by mitomycin C or by HSV-tk /GCV system compared to that with viable HuH7 cells. In contrast, at an E / T ratio of 100, the production was significantly augmented with apoptotic HuH7 cells induced by both mitomycin C and HSV-tk /GCV system (Fig 4B ) . Although the cytotoxic activity was not observed in vitro, these results suggest that the induction of apoptosis in HuH7 cells may enhance TNF -production of macrophages, which contributes to the antitumor effects in vivo. . Cytotoxic activity and TNF -production of macrophages exposed to apoptotic HuH7 cells in vitro. Mouse peritoneal macrophages activated by IFN -and LPS were cocultured with 51 Cr -labeled HuH7 cells mixed with the same number of viable HuH7 cells or apoptotic HuH7 cells, which were induced by either mitomycin C or HSV -tk / GCV system. After 18 hours of incubation, release was determined and TNF -concentration in the culture media was measured at the same time. Percent specific cytotoxicity was calculated according to the following equation: [ 100Â( experimental release À spontaneous release ) / ( maximal release À spontaneous release ) ]. Spontaneous release was determined from target cells only, and maximal release was from target cells treated with 1% Triton X. Experiments were performed three times and results were expressed as means ± SE. A: Cytotoxicity assay. B: TNF -production. 51 Cr 
Characterization of apoptotic HuH7 cells induced by HSV -tk / GCV
The observations in vitro suggested that macrophages could be activated not only by MCP -1, but also by apoptotic tumor cells treated with mitomycin C or HSV-tk /GCV. By flow cytometric analysis, HuH7 cells, which were treated with HSV-tk /GCV, revealed enhancement of PI staining, reduction of size, and cellular shrinkage (Fig 5A ) , compared with that with rAd infection alone ( Fig 5B ) or without any treatment (Fig 5C ) . These results indicate that apoptosis of HuH7 cells was induced when they were treated with HSVtk / GCV. Next, to estimate whether HuH7 cells exhibit apoptosis when treated with HSV-tk /GCV in vivo, tumor foci established by subcutaneous injection of HuH7 cells were infected with the rAd -expressing HSV-tk, AxA2ATK, followed by intraperitoneal GCV administration. Two and 4 days after the start of GCV administration, the tumor tissues were resected and the numbers of tumor cells that displayed the diagnostic cytological features characteristic of apoptosis ( nuclear chromatin margination, cytoplasmic condensation, and fragmentation ) were histopathologically counted. In tumor tissues treated with AxA2ATK and GCV, more apoptotic cells were detected 2 days after the start of GCV ( Fig 6A, Table 1 ) compared to those infected with AxA2ANCre and GCV or AxA2ATK and PBS as controls ( Fig 6B, Table 1) . Then, the number of apoptotic cells decreased 4 days after the start of GCV ( Table 1) . These results indicate that xenografted HuH7 tumors exhibit apoptosis when treated with HSV-tk /GCV in vivo.
Anti -tumor effects of HSV -tk / GCV system and adenovirally delivered MCP -1 in vivo Finally, to estimate whether induction of apoptosis by HSVtk / GCV concomitant with MCP -1 treatment enhances antitumor effect in vivo, subcutaneous tumor foci of HuH7 cells established in athymic nude mice were transduced with the rAd -harboring HSV-tk gene, AxA2ATK, followed by GCV administration as described in the Characterization of Apoptotic HuH7 Cells Induced by HSV-tk /GCV section. Two days after the start of GCV treatment, rAd harboring an expressible MCP -1, AxCAMCP -1, was injected into tumor foci and tumor development was monitored (Fig 7) . The growth of HuH7 tumor was markedly suppressed when treated with both AxA2ATK / GCV and AxCAMCP -1. In contrast, the growth of tumor foci was only partially suppressed until 24 days when tumors were injected either with AxA2ATK /GCV and AxCANZ, or AxA2ANZ /GCV and AxCAMCP -1. In the latter cases, tumors grew very rapidly thereafter.
Furthermore, histopathological analysis showed that incidences of apoptotic and necrotic tumor cells and mononuclear cell infiltration were induced to a greater extent in the tumor foci treated with both the rAds AxA2ATK / GCV and AxCAMCP -1 (Fig 8A ) than those treated with the rAd AxA2ATK /GCV and the control rAd SAKAI, KANEKO, NAKAMOTO, ET AL: IMMUNE-GENE THERAPY WITH MCP -1 AND SUICIDE GENE AxCANZ ( Fig 8B ) . In immunohistochemical analysis, most of the infiltrating mononuclear cells observed in the tumor foci were immunohistochemically stained with antibodies against a macrophage marker Mac -1 (Fig 8C ) , but not stained with control IgG ( Fig 8E ) . The tumor foci treated with AxA2ANZ /GCV and AxCAMCP -1 also revealed the accumulation of Mac -1 -positive cells (Fig 8F ) . The number of accumulated Mac -1-positive cells in this treatment was similar to that of tumors which received the treatment of MCP -1 with HSV-tk /GCV. On the other hand, those positive cells were not detected when tumors were treated with the control rAd AxCANZ instead of AxCAMCP-1 ( Fig  8D ) . Moreover, the synergistic antitumor effects induced by the HSV-tk / GCV system and transduced MCP -1 disappeared in animals when carrageenan, a compound known to inactivate macrophage in vivo, was administered on days 3 -7 and on days 14, 21, and 28 ( Fig 7 ) . Collectively, these results indicate that the antitumor effects of the HSV-tk / GCV system were enhanced synergistically by the MCP -1 transduction due to the recruitment and activation of macrophages in tumor tissues.
DISCUSSION
The current study revealed the synergistic effect of adenovirally delivered MCP -1 in killing HCC cells in vivo when combined with the HSV-tk /GCV suicide gene system. The synergistic antitumor effect of MCP -1 was dependent on the recruitment and activation of macrophages because macrophage infiltration was immunohistochemically detected in MCP -1-delivered tumor tissues, and, more importantly, because the antitumor effect of delivered MCP -1 was markedly reduced by the administration of carrageenan, a compound known to inactivate macrophages in vivo. 43 Although the transfectant -derived MCP -1 has been reported to regulate both the recruitment and activation of monocytes /macrophages to tumor tissues, 23 -25 we found the synergistic effect of MCP -1 when combined with a suicide gene system on tumor regression.
Although rAd is a well -characterized viral vector for cancer gene therapy with a very high efficiency of gene delivery, 13 the delivered gene is expressed only in a small percentage of the tumor cells in solid cancers. Consistent with this observation, successful application of suicide gene therapy relies on the bystander effect in which nontransduced tumor cells are killed in the presence of a minority of cells expressing the suicide gene that phosphorylates GCV. GCV metabolites produced in the HSV-tk -transduced tumor cells are transferred to neighboring nontransduced cells through gap junctions. 16 Immune -mediated antitumor effects via macrophages, T lymphocytes, or NK cells are also involved in the bystander effect of HSV-tk -transduced tumor cells. 45 In the current study, to enhance the bystander effect, MCP -1 gene was introduced adenovirally into tumor tissues in which apoptosis had been induced by the suicide gene system. The results showed that MCP -1 induced antitumor effects together with tumor cell apoptosis induced by the HSV-tk /GCV system. MCP -1 has been reported to suppress growth and metastasis of multidrug -resistant lung cancer cells treated with the anti -P -glycoprotein antibody that induces antibody -dependent cellular cytotoxicity to the tumor cells in vivo. 46, 47 In support of this notion, the treatment with both HSV-tk / GCV and MCP -1 was more effective in killing HCC cells than that with either HSV-tk / GCV or MCP -1. Thus, MCP -1 may be used to induce tumor regression of HCC even in combination with suicide gene delivery.
To understand the cellular basis of the possible synergism of the HSV-tk /GCV system and MCP -1 in tumoricidal effects in vivo, the killing activity and TNF -production of mouse peritoneal macrophages exposed to apoptotic tumor cells were evaluated in vitro. When macrophages were exposed to apoptotic tumor cells, their production of TNF -, a tumoricidal cytokine, 44 was markedly increased. Based on this observation, it is likely that increased TNF -production of macrophages exposed to apoptotic HuH7 cells might account for the synergistic antitumor effects induced by codelivery of HSV-tk /GCV system and MCP-1 in vivo.
In the present experimental system, antitumor effects were evaluated in athymic nude mice in which T lymphocytemediated immune responses were abolished although the number and biological function of monocytes /macrophages are preserved. 48 It is possible that the antitumor effects observed could be enhanced in immunocompetent mice because the recruited / activated macrophages in tumor tissues induced T lymphocyte -mediated immune responses by secreting proinflammatory cytokines, such as TNF -.
Although the data presented here appear to be promising, a number of problems remain to be solved for the clinical application. First, subcutaneous tumor models of an HCC cell line may not be relevant to HCCs in patients. However, in cases of nonsurgical procedures for HCC treatment in patients, such as percutaneous ethanol injection therapy, percutaneous microwave coagulation therapy, 49 and radiofrequency ablation, 50 administration of the current rAd vectors could be easily applicable immediately after the standard nonsurgical procedures to ensure tumor cell killing. Furthermore, rAd might elicit its immunogenicity or cytotoxicity 51 when administered in HCC patients, especially when spread out through blood flow. The high doses of rAds currently used could also cause severe unexpected side effects. 51 Although the problems of rAd vectors need to be resolved for clinical application, the current study has raised the possibility of a new strategy of immune gene therapy accompanied by a suicide gene system in treating HCC and tumors of other lineages.
